AP NEWS

Frontotemporal Lobe Dementia - 2018-2028 - ResearchAndMarkets.com

July 12, 2018

DUBLIN--(BUSINESS WIRE)--Jul 12, 2018--The “Epiomic Epidemiology Series: Frontotemporal Lobe Dementia Forecast In 19 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.

This report provides the current prevalent population for FTD across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort.

Along with the current prevalence, the report provides a breakdown of the sub-group classifications of the disease, disease origin and tau protein mutations in the FTD patient population. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of FTD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for FTD include:

Dementia and cognitive disorders Speech and semantic problems Limb/muscle weakness and rigidity Behavioural disorders Appetite changes

Reasons to buy

Able to quantify patient populations in global FTD market to target the development of future products, pricing strategies and launch plans. Gain further insight into the prevalence of the subdivided types of FTD and identify patient segments with high potential. Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries. Provide a level of understanding on the impact from specific co-morbid conditions on FTD prevalent population. Examination of the prevalence for different causative protein mutations in FTD. Identify sub-populations within FTD which require treatment. Gain an understanding of the specific markets that have the largest number of FTD patients.

Key Topics Covered:

Cause of the Disease Risk Factors & Prevention Diagnosis of the Disease Variation by Geography/Ethnicity Disease Prognosis & Clinical Course Key Comorbid Conditions/Features Associated with the Disease Methodology for Quantification of Patient Numbers Top-Line Prevalence for FTD Features of FTD Patients Classification Genetic Background Neurological/Behavioural Symptoms Comorbidities of FTD Patients Other Services & Solutions Online Epidemiology Databases Online Pharmaceutical Pricing Database

For more information about this report visit https://www.researchandmarkets.com/research/r5kl66/frontotemporal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180712005597/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/12/2018 11:10 AM/DISC: 07/12/2018 11:10 AM

http://www.businesswire.com/news/home/20180712005597/en

AP RADIO
Update hourly